vs
ANAVEX LIFE SCIENCES CORP.（AVXL）与Arcadia Biosciences, Inc.（RKDA）财务数据对比。点击上方公司名可切换其他公司
ANAVEX LIFE SCIENCES CORP.的季度营收约是Arcadia Biosciences, Inc.的1.2倍（$1.1M vs $901.0K），Arcadia Biosciences, Inc.净利率更高（-148.3% vs -526.5%，领先378.2%），ANAVEX LIFE SCIENCES CORP.同比增速更快（-22.6% vs -25.8%），过去两年Arcadia Biosciences, Inc.的营收复合增速更高（-4.5% vs -21.6%）
Anavex Life Sciences Corp是一家临床阶段生物制药企业，专注于开发针对阿尔茨海默病、雷特综合征、帕金森病等神经退行性及神经发育障碍的小分子创新疗法，主要业务覆盖北美及欧洲市场，面向存在未满足医疗需求的患者群体。
阿卡迪亚生物科学是一家美国上市农业生物技术企业，总部位于加利福尼亚州戴维斯，专注于开发可提升作物品质与产量的作物性状改良技术，该公司部分股权归道德指南针公司所有。
AVXL vs RKDA — 直观对比
营收规模更大
AVXL
是对方的1.2倍
$901.0K
营收增速更快
AVXL
高出3.2%
-25.8%
净利率更高
RKDA
高出378.2%
-526.5%
两年增速更快
RKDA
近两年复合增速
-21.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1M | $901.0K |
| 净利润 | $-5.7M | $-1.3M |
| 毛利率 | — | 21.4% |
| 营业利润率 | -628.5% | -152.8% |
| 净利率 | -526.5% | -148.3% |
| 营收同比 | -22.6% | -25.8% |
| 净利润同比 | 53.1% | 67.1% |
| 每股收益（稀释后） | $-0.06 | $-0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVXLRKDA
| Q4 25 | $1.1M | $901.0K | ||
| Q3 25 | $999.0K | $1.3M | ||
| Q2 25 | $1.1M | $1.5M | ||
| Q1 25 | $1.2M | $1.2M | ||
| Q4 24 | $1.4M | $1.2M | ||
| Q3 24 | $1.8M | $1.5M | ||
| Q2 24 | $1.8M | $1.3M | ||
| Q1 24 | $1.8M | $987.0K |
净利润AVXLRKDA
| Q4 25 | $-5.7M | $-1.3M | ||
| Q3 25 | $-9.8M | $856.0K | ||
| Q2 25 | $-13.2M | $-4.5M | ||
| Q1 25 | $-11.2M | $2.6M | ||
| Q4 24 | $-12.1M | $-4.1M | ||
| Q3 24 | $-11.6M | $-1.6M | ||
| Q2 24 | $-12.2M | $1.1M | ||
| Q1 24 | $-10.5M | $-2.4M |
毛利率AVXLRKDA
| Q4 25 | — | 21.4% | ||
| Q3 25 | — | 32.1% | ||
| Q2 25 | — | 43.4% | ||
| Q1 25 | — | 43.2% | ||
| Q4 24 | — | 31.9% | ||
| Q3 24 | — | 32.9% | ||
| Q2 24 | — | 51.5% | ||
| Q1 24 | — | 52.3% |
营业利润率AVXLRKDA
| Q4 25 | -628.5% | -152.8% | ||
| Q3 25 | -1085.5% | -88.5% | ||
| Q2 25 | -1345.0% | -34.4% | ||
| Q1 25 | -1034.1% | 44.2% | ||
| Q4 24 | -975.0% | -187.7% | ||
| Q3 24 | -810.9% | -114.5% | ||
| Q2 24 | -813.1% | — | ||
| Q1 24 | -718.9% | -160.9% |
净利率AVXLRKDA
| Q4 25 | -526.5% | -148.3% | ||
| Q3 25 | -983.7% | 65.7% | ||
| Q2 25 | -1231.9% | -306.4% | ||
| Q1 25 | -925.3% | 216.6% | ||
| Q4 24 | -868.8% | -334.5% | ||
| Q3 24 | -660.2% | -104.9% | ||
| Q2 24 | -680.1% | 81.2% | ||
| Q1 24 | -600.6% | -245.5% |
每股收益（稀释后）AVXLRKDA
| Q4 25 | $-0.06 | $-0.97 | ||
| Q3 25 | $-0.11 | $0.62 | ||
| Q2 25 | $-0.16 | $-3.26 | ||
| Q1 25 | $-0.13 | $1.90 | ||
| Q4 24 | $-0.14 | $-2.99 | ||
| Q3 24 | $-0.14 | $-1.18 | ||
| Q2 24 | $-0.14 | $0.78 | ||
| Q1 24 | $-0.13 | $-1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $131.7M | $4.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $126.6M | $4.1M |
| 总资产 | $133.0M | $6.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AVXLRKDA
| Q4 25 | $131.7M | $4.6M | ||
| Q3 25 | $102.6M | $5.9M | ||
| Q2 25 | $101.2M | $4.4M | ||
| Q1 25 | $115.8M | $3.2M | ||
| Q4 24 | $120.8M | $4.2M | ||
| Q3 24 | $132.2M | $6.6M | ||
| Q2 24 | $138.8M | $8.1M | ||
| Q1 24 | $139.4M | $8.5M |
股东权益AVXLRKDA
| Q4 25 | $126.6M | $4.1M | ||
| Q3 25 | $94.9M | $5.4M | ||
| Q2 25 | $91.0M | $4.5M | ||
| Q1 25 | $99.8M | $8.9M | ||
| Q4 24 | $110.9M | $6.2M | ||
| Q3 24 | $120.3M | $10.3M | ||
| Q2 24 | $129.8M | $11.7M | ||
| Q1 24 | $135.0M | $10.6M |
总资产AVXLRKDA
| Q4 25 | $133.0M | $6.5M | ||
| Q3 25 | $103.8M | $8.6M | ||
| Q2 25 | $102.4M | $7.8M | ||
| Q1 25 | $117.1M | $13.0M | ||
| Q4 24 | $124.0M | $13.5M | ||
| Q3 24 | $135.6M | $15.2M | ||
| Q2 24 | $141.5M | $17.4M | ||
| Q1 24 | $144.5M | $16.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-7.2M | $-861.0K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AVXLRKDA
| Q4 25 | $-7.2M | $-861.0K | ||
| Q3 25 | $-8.6M | $-257.0K | ||
| Q2 25 | $-12.5M | $-2.0M | ||
| Q1 25 | $-5.9M | $-1.6M | ||
| Q4 24 | $-12.1M | $-2.2M | ||
| Q3 24 | $-6.7M | $-1.8M | ||
| Q2 24 | $-5.2M | $-2.5M | ||
| Q1 24 | $-11.7M | $-3.2M |
自由现金流AVXLRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-2.5M | ||
| Q1 24 | — | $-3.2M |
自由现金流率AVXLRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -188.3% | ||
| Q1 24 | — | -326.5% |
资本支出强度AVXLRKDA
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 1.3% |
现金转化率AVXLRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | -0.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.61× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.31× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
